Skip to main content
    Assistive Tools | Loop | Staff | Library | Vacancies | What's On
Home Dublin City University
  • Courses
    • DCU Open Days
    • Study at DCU
    • Undergraduate
    • CAO Hub
    • Postgraduate Hub
    • DCU Micro-Credentials
    • Scholarships
    • Admissions Information
    • Accommodation
    • Graduate Studies Office
    • Student Recruitment
  • Research
    • Research at DCU
    • DCU Research Portal
    • Research Support Services
    • Research Impact
    • Graduate Studies Office
    • DCU:Innovate Hub
    • DCU:Innovate Enterprise
    • Life Sciences Institute
  • DCU Global
  • Engagement
    • INTRA Internships
    • Courses with INTRA
    • Engagement
      • DCU Engagement
      • The Engagement Hub
      • DCU Alumni
      • DCU in the Community
      • DCU Arts and Culture
      • Age Friendly University
    • DCU Placement
    • DCU Educational Trust
    • DCU International Academy
    • Centre for Talented Youth, Ireland
    • National Institute for Digital Learning
    • DCU Campus Store
    • DCU Sport
    • The Helix
    • Changemaker Schools Network
  • Support
    • Student Support & Development
      • Counselling & Personal Development
      • Student Health Service
      • Student Policies
      • Financial Assistance Service
      • Chaplaincy
      • House of Accessibility
    • Student Advice Centre
    • DCU Healthy
    • Accessible Campus
    • Registry
    • Transcripts
    • Current Students
      • Orientation
      • Examinations
      • Examination Results
      • Fees Information
      • Academic Calendars
      • Digital Technology Solutions (DTS)
    • Student Life
      • DCU Students Union
      • Clubs & Societies
      • DCUFM
    • DCU Autism Friendly
    • Disability & Learning Support Service
    • DCU Access
    • Mature Students
    • Careers Service
    • International Students
  • Faculties
    • DCU Business School
    • DCU Institute of Education
    • Faculty of Engineering & Computing
    • Faculty of Humanities & Social Sciences
    • Faculty of Science & Health
    • DCU Connected
  • More
    • Office of the President
      • DCU Strategic Plan (2023-2028)
    • Office of the COO
      • OCOO
      • Sustainability at DCU
      • DCU Governing Authority
      • Estates
      • Freedom of Information
      • Health & Safety
      • Oifig na Gaeilge
      • University Policies
    • Office of the Vice President of Academic Affairs
      • Graduate Studies
      • DCU SIS
    • Office of the Executive Director of Engagement
    • Office of the Vice President for Research
    • Offices & Departments
      • Communications, Marketing & Events
      • Estates
      • Finance
      • DCU People
      • Digital Technology Solutions (DTS)
      • Language Translation Services
      • Registry
      • Quality and Institutional Insights Office
      • Teaching Enhancement Unit (TEU)
    • Campus
      • How to get here
      • Inter-Faith Centre
      • Parking
      • Pharmacy
  • Home
  • Primary School students
  • Secondary School students
  • Programmes
  • Research
  • Events
  • Contact Us
  • Home
  • Framework
  • Policies
  • Classification Calculator
  • Guidelines
  • Training
  • Contact
  • Home
  • Programme
  • Committees
  • Your visit
  • Contact
  • Home
  • People
  • About Us
  • Research
  • Annual Conference
  • Contact Us
  • Home
  • Student Hub
  • Research Hub
  • Learning Support
  • Visit and Study
  • Find and Borrow
  • Ask Us
  • Home
  • Our Story
  • Cancer Research
  • Our People
  • Work With Us
  • Research
  • Contact Us
<< Back to LSI Cancer Research
LSI Cancer Research

Gene editing technologies (inc. CRISPR Cas9) Projects

AllCaN pancreatic

Alterations in genes of the DNA damage response (DDR) represent a significant subset of actionable genetic alterations in pancreatic cancer, particularly due to their association with homologous recombination repair deficiency (HRD). PARP inhibitors (PARPi), such as olaparib, have emerged as a promising therapeutic strategy for BRCA2-mutant PDAC by exploiting synthetic lethality. However, several challenges limit their widespread application. Tumour heterogeneity, the development of resistance mechanisms and the lack of reliable response biomarkers diminishes the efficacy of PARP inhibitors.This study will establish novel therapeutic strategies for increasing the efficacy of DDR agents in PDAC, refine biomarkers to select for patients most likely to respond (or not) to PARPi, and will offer innovative interventions to overcome inherent and acquired PARPi resistance. Here we will build rationale from pre-clinical experiments that have potential to translate to early-phase clinical trials bringing together design and testing of synthetic combination strategies and associated companion biomarkers.



Why It Matters

Targeted DDR agents such as PARP inhibitors have shown promise in BRCA2 mutated pancreatic cancers. However patients with DDR alterations (non-BRCA2) may also benefit from PARPi or other DDR inhibitor drugs.
 

Patient Focus
Identify new pharmacological or genomic variant synthetic lethality with DDR inhibitors
Cancer Type
Pancreatic Cancer
Expertise
3D organoid/advanced co culture models, Gene editing technologies (inc. CRISPR Cas9), Drug screening platforms
Funders
Breakthrough Cancer Research
Principal Investigator(s)
Naomi Walsh
Team Members
Karla Jenkac, Alex Eustace
Additional Links
View Project Page   
The role of non-coding mutations as predictors of treatment response in breast cancer
Shows project team

Breast cancer remains the leading cause of cancer deaths among women, even though diagnosis and treatment have improved greatly. Current treatments can only target specific genetic changes (mutations) in about 40% of patients, which means many women don’t benefit from existing options. This shows the need to find new drug targets.

Traditionally, researchers have focused on mutations in the parts of our DNA that make proteins. But growing evidence shows that changes in the “non‑coding” regions of DNA—areas that don’t directly make proteins—can also drive cancer. These non‑coding mutations may serve as important markers for developing new treatments or choosing the right therapy.

Large studies that look at the entire genome have already found promising non‑coding mutations in breast cancer patients. The challenge now is figuring out which of these changes actually drive cancer and which are harmless. Studying and testing these mutations is essential to deepen our understanding of breast cancer and to create more precise, personalised treatments that improve patient care.
 



Why It Matters

Scientists need to functionally determine the role of frequently occurring oncogenic non-coding mutations to identify those that drive cancer and could act as predictors of therapy response.

Patient Focus
Identifying the role of non-coding mutations on disease severity and treatment response
Cancer Type
Breast Cancer
Expertise
Cell cloning, Gene editing technologies (inc. CRISPR Cas9), Reporter assays, Epigenetic profiling
Funders
Research Ireland, Health Research Board and Cancer Clinical Research Trust
Principal Investigator(s)
Alex Eustace
Team Members
Dr Arnau Cuy Saques, Jane Herlihy
Additional Links
View Project Page   
  • Student Apps
  • Student Email
  • Staff Apps
  • Staff Email
  • Contact Us
  • Loop
  • Disclaimer
  • Privacy and Cookies
  • Accessibility Statement
  • AI in DCU
Facebook Icon
YouTube Icon
Instagram Icon
Tik Tok Icon
LinkedIn Icon
Bluesky Icon
  • The Helix logo
  • ESF logo
  • EU Structural Funds logo
Dublin City University is a registered charity with the Charities Regulatory Authority, RCN 20013653.